Investigation of improved nasal high flow to enhance CO2 clearance and maintain oxygen saturation during shared airway surgery

Fisher & Paykel Healthcare0 个研究点目标入组 90 人开始时间: 2019年4月24日最近更新: 2024年7月8日

适应症

试验速览

暂无简介。

•18 years and over and less than 80 years in age
•Capable of informed consent
•Undergoing laryngotrachael surgery under general anaesthetic expected to last at least 15 minutes

•BMI > 35 kg/m2.
•Patients who are deemed unfit for general anaesthesia and/or THRIVE treatment by the anaesthetist.
•Room-air saturation levels <85%
•requiring preoperative oxygen therapy secondary to chronic lung disease
•Pre-existing hypoxemia
•clinically-defined severe concomitant lower airway pulmonary disease
•Known contraindication to Optiflow™ device
•Patients in whom CPAP is contraindicated (e.g. pneumothorax, bullous lung disease, craniofacial trauma, airway, foreign body, unstable haemodynamics)
•history or symptoms of increased intracranial pressure or reduced intracranial compliance ( e.g. headaches, nausea and vomiting, visual changes, mental changes) .
•skull base defects.
•Patients in whom high FiO2 is contraindicated (e.g. patients being treated with Bleomycin)
•Patients undergoing procedures with electrocautery or laser.
•More than 50% (as judged by the anaesthetist) of the nares occluded by the nasal prongs
•Bleeding in nose or oropharynx
•Patients receiving an induction with volatile anaesthetics
•Patients with delicate skin that could be thermally damaged by the transcutaneous monitor

发起方